Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
Completed · Phase 1
Conditions studied: Hepatocellular Carcinoma, Liver Cancer, Localized Unresectable Liver Cancer
In brief
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: This phase I trial is studying side effects and best dose of sorafenib tosylate when given together with chemoembolization in treating patients with unresectable liver cancer.
Key facts
- Study ID
- NCT01042041
- Run by
- Abramson Cancer Center at Penn Medicine
- People needed
- 18
- Starts
- 2009-09-01
- Expected to finish
- 2010-12-01
- Last updated by the study team
- 2013-02-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.